nach oben

Erschienen in:

26.08.2016 | Research Paper

Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells

verfasst von: Powrnima Joshi, Mitra Kooshki, Wayne Aldrich, Daniel Varghai, Maciej Zborowski, Arun D. Singh, Pierre L. Triozzi

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Natural killer (NK) cells are implicated in the control of metastasis in uveal melanoma, a process that has been ascribed to its cancer stem cell subpopulation. NK cell activation is regulated by specific microRNA (miR). The NK cell sensitivity and regulatory miR production of uveal melanoma cancer stem cells was examined. Cancer stem cells enriched from aggressively metastatic MUM2B uveal melanoma cells by selecting CD271⁺ cells or propagating as non-adherent spheres in stem-cell supportive were more resistant to NK cell cytolysis than cancer stem cells enriched from less aggressively metastatic OCM1 uveal melanoma cells. Both MUM2B and OCM1 cells expressed and secreted NK cell regulatory miRs, including miR 146a, 181a, 20a, and 223. MUM2B cells expressed and secreted miR-155; OCM1 cells did not. Transfecting MUM2B cells with anti-miR-155 increased NK cell sensitivity. CD271⁺ cells were identified in the blood of patients with metastatic uveal melanoma and were characterized by low expression of melanocyte differentiation determinants and by the ability to form non-adherent spheres in stem-cell supportive media. These cells also expressed NK cell regulatory miRs, including miR-155. These results indicate that uveal melanoma cancer stem cells can vary in their sensitivity to NK cell lysis and their expression of NK cell regulatory miRs. Circulating CD271⁺ cells from patients with metastatic uveal melanoma manifest cancer stem cell features and express miRs associated with NK cell suppression, including miR-155, that may contribute to metastatic progression.

Nur mit Berechtigung zugänglich

Dithmar S, Rusciano D, Lynn MJ, Lawson DH, Armstrong CA, Grossniklaus HE (2000) Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol 118:1085–1089CrossRefPubMed

Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ (1997) Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Investig Ophthalmol Vis Sci 38:1865–1872

Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O (2001) Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Investig Ophthalmol Vis Sci 42:2153–2156

Vetter CS, Lieb W, Bröcker EB, Becker JC (2004) Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 91:1495–1499PubMedPubMedCentral

Ma D, Luyten GP, Luider TM, Niederkorn JY (1995) Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Investig Ophthalmol Vis Sci 36:435–441

Blom DJ, De Waard-Siebinga I, Apte RS, Luyten GP, Niederkorn JY, Jager MJ (1997) Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines. Melanoma Res 7:103–109CrossRefPubMed

Repp AC, Mayhew ES, Apte S, Niederkorn JY (2000) Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 165:710–715CrossRefPubMed

Jager MJ, Hurks HM, Levitskaya J, Kiessling R (2002) HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 63:444–451CrossRefPubMed

Chang SH, Worley LA, Onken MD, Harbour JW (2008) Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 18:191–200CrossRefPubMed

10.

Kalirai H, Damato BE, Coupland SE (2011) Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Investig Ophthalmol Vis Sci 52:8458–8466CrossRef

11.

Thill M, Berna MJ, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager MJ, Richard G, Lange C, Gehling UM (2011) Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res 21:405–416CrossRefPubMed

12.

Valyi-Nagy K, Kormos B, Ali M, Shukla D, Valyi-Nagy T (2012) Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures. Mol Vis 18:588–592PubMedPubMedCentral

13.

Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW (2013) BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 13:371CrossRefPubMedPubMedCentral

14.

Torres V, Triozzi P, Eng C, Tubbs R, Schoenfiled L, Crabb JW, Saunthararajah Y, Singh AD (2011) Circulating tumor cells in uveal melanoma. Future Oncol 7:101–109CrossRefPubMed

15.

Murphy GF, Wilson BJ, Girouard SD, Frank NY, Frank MH (2014) Stem cells and targeted approaches to melanoma cure. Mol Asp Med 39:33–49CrossRef

16.

Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L (2011) Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 71:3098–3109CrossRefPubMed

17.

Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A (2010) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5:e11590CrossRefPubMedPubMedCentral

18.

Tseng HC, Inagaki A, Bui VT, Cacalano N, Kasahara N, Man YG, Jewett A (2015) Differential targeting of stem cells and differentiated glioblastomas by NK cells. J Cancer 6:866–876CrossRefPubMedPubMedCentral

19.

Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L, Mingari MC (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793–801CrossRefPubMed

20.

Liu C, Tang DG (2011) MicroRNA regulation of cancer stem cells. Cancer Res 71:5950–5954CrossRefPubMedPubMedCentral

21.

Cichocki F, Felices M, McCullar V, Presnell SR, Al-Attar A, Lutz CT, Miller JS (2011) Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol 187:6171–6175CrossRefPubMedPubMedCentral

22.

Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, Caligiuri MA (2012) miR-155 regulates IFN-γ production in natural killer cells. Blood 119:3478–3485CrossRefPubMedPubMedCentral

23.

Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER (2010) Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res 20:1590–1604CrossRefPubMedPubMedCentral

24.

Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z (2015) miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle 14:243–252CrossRefPubMedPubMedCentral

25.

Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065–1073CrossRefPubMed

26.

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659CrossRefPubMed

27.

He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister CC, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu J (2013) MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood 121:4663–4671CrossRefPubMedPubMedCentral

28.

Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL (2014) Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol 58:182–186CrossRefPubMed

29.

Folberg R, Kadkol SS, Frenkel S, Valyi-Nagy K, Jager MJ, Pe’er J, Maniotis AJ (2008) Authenticating cell lines in ophthalmic research laboratories. Investig Ophthalmol Vis Sci 49:4697–4701CrossRef

30.

Folberg R, Leach L, Valyi-Nagy K, Lin AY, Apushkin MA, Ai Z, Barak V, Majumdar D, Pe’er J, Maniotis AJ (2007) Modeling the behavior of uveal melanoma in the liver. Investig Ophthalmol Vis Sci 48:2967–2974CrossRef

31.

Duan F, Lin M, Li C, Ding X, Qian G, Zhang H, Ge S, Fan X, Li J (2014) Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells. Cancer Biol Ther 15:544–559CrossRefPubMedPubMedCentral

32.

Truzzi F, Marconi A, Lotti R, Dallaglio K, French LE, Hempstead BL, Pincelli C (2008) Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. J Investig Dermatol 128:2031–2040CrossRefPubMed

33.

Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA (2013) MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol 191:5904–5913CrossRefPubMed

34.

Elemam NM, Mekky RY, El-Ekiaby NM, El Sobky SA, El Din MA, Esmat G, Abdelaziz AI (2015) Repressing PU.1 by miR-29a∗ in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. Hum Immunol 76:687–694CrossRefPubMed

35.

Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, Jager MJ, Froelich CJ, Kiessling R, Levitsky V, Levitskaya J (2008) Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180:3766–3774CrossRefPubMed

36.

Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, Caporaso P, Bondanza S, Antonetti FR, Bonmassar E, Martelli F, Alvino E, D’Atri S (2011) MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 24:538–550CrossRefPubMed

37.

Liu F, Kong X, Lv L, Gao J (2015) TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett 359:288–298CrossRefPubMed

38.

Ji J, Zheng X, Forgues M, Yamashita T, Wauthier EL, Reid LM, Wen X, Song Y, Wei JS, Khan J, Thorgeirsson SS, Wang XW (2015) Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology 62:829–840CrossRefPubMedPubMedCentral

39.

Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS, Zhou T (2013) Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med 31:1375–1380PubMed

40.

Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33:679–689CrossRefPubMed

41.

Tomellini E, Lagadec C, Polakowska R, Le Bourhis X (2014) Role of p75 neurotrophin receptor in stem cell biology: more than just a marker. Cell Mol Life Sci 71:2467–2481CrossRefPubMed

42.

Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R (2014) CD271 is an imperfect marker for melanoma initiating cells. Oncotarget 5(5272–83):39

43.

Bergeron MA, Champagne S, Gaudreault M, Deschambeault A, Landreville S (2012) Repression of genes involved in melanocyte differentiation in uveal melanoma. Mol Vis 18:1813–1822PubMedPubMedCentral

44.

Landreville S, Lupien CB, Vigneault F, Gaudreault M, Mathieu M, Rousseau AP, Guerin SL, Salesse C (2011) Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization. Mol Vis 17:1324–1333PubMedPubMedCentral

45.

Melamed I, Kelleher CA, Franklin RA, Brodie C, Hempstead B, Kaplan D, Gelfand EW (1996) Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140trk. Eur J Immunol 26:1985–1992CrossRefPubMed

46.

Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66:7341–7347CrossRefPubMed

47.

Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, Smit EF (2010) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 102:268–275CrossRefPubMed

48.

Damato B, Coupland SE (2009) Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 127:423–429CrossRefPubMed

49.

Onken MD, Worley LA, Tuscan MD, Harbour JW (2010) An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 12:461–468CrossRefPubMedPubMedCentral

50.

Ferracin M, Veronese A, Negrini M (2010) Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 10:297–308CrossRefPubMed

51.

Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, Sempere LF, Conejo-Garcia JR (2012) Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 72:1683–1693CrossRefPubMedPubMedCentral

52.

Jackson A, Linsley PS (2010) The therapeutic potential of microRNA modulation. Discov Med 9:311–318PubMed

Titel: Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells
verfasst von: Powrnima Joshi
Mitra Kooshki
Wayne Aldrich
Daniel Varghai
Maciej Zborowski
Arun D. Singh
Pierre L. Triozzi
Publikationsdatum: 26.08.2016
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 8/2016
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-016-9815-9

Springer Medizin

Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas

CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy

Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer

Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes

A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie